

Board Meeting in Public Tuesday, 24 September 2024

Title of Report	Governance Update		Agenda No.	5.1
Nature of Report	⊠ Official	□ Official Sensitive		
Author(s)	Silena Dominy, Company Secretary			
Lead Executive	Helen Gillan, Director of Quality			
Non-Executive Director Sponsor	Peter Wyman, Chair			
Presented for	☑ Approval☐ Information☐ Assurance☑ Update			
Executive Summary				
This report provides the Board with an update on corporate governance matters in NHS Blood and Transplant (NHSBT), with the main focus for this meeting being on the confirmation of Board appointments by DHSC and Executive Directors appointments on or at Board Committees. As a follow up to the Board's review of its Skills and Capabilities review a Board development plan is proposed for approval. The plan is intentionally an evolving plan which will flex and change in view of need throughout the year, however the base activity addresses areas highlighted by the review as being beneficial to a number of Board members. Details of the upcoming Board effectiveness review are also provided for information.				
Previously Considered by				
N/A				
Recommendation	 The Board is asked to note the Governance update and specifically to approve the amendments to Executive Director membership/attendance at Board Committees. The Board is asked to approve the Board development plan. 			
Risk(s) identified (Link to Board Assurance Framework Risks)				
BAF P11 Corporate Governance "There is a risk that the Board do not have full oversight of significant risk caused by ineffective systems or their application resulting in uninformed decision-making, a requirement for emergency management, suboptimal outcomes and reputational damage" The frequent review of governance arrangements ensures continuous improvement and oversight. It reduces the likelihood of the Board not fulfilling its duties, or stepping outside of its powers, therefore strengthens governance.				
Strategic Objective(s) this paper relates to:				
 ☑ Collaborate with partners ☑ Invest in people and culture ☑ Drive innovation ☑ Grow and diversify our donor base 				
Appendices: A – Board Development Plan				